Metabolism and distribution of two highly potent and selective peptidomimetic inhibitors of matriptase

Xenobiotica

Volumn 40, Issue 2, 2010, Pages 93-101

  Kotthaus, J ^a   Steinmetzer, T ^b   Schade, D ^a   Van De Locht, A ^c   Clement, B ^a  

^a UNIVERSITY OF KIEL   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c The Medicines Company (Leipzig) GmbH   (Germany)

Author keywords

Amidine; Matriptase; Metabolism; Serine protease inhibitor; Species differences

Indexed keywords

CJ 1737; CJ 672; MATRIPTASE; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; BILIARY EXCRETION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HYDROLYSIS; DRUG METABOLISM; DRUG STABILITY; DRUG STRUCTURE; ENZYME INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MASS SPECTROMETRY; MOUSE; NONHUMAN; RAT;

AMIDINES; ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, LIQUID; COLON; DOGS; ENZYME INHIBITORS; HUMANS; INJECTIONS, INTRAPERITONEAL; KIDNEY; LIVER; LUNG; MASS SPECTROMETRY; MICE; MYOCARDIUM; PHENYLALANINE; RATS; SERINE ENDOPEPTIDASES; SPECIES SPECIFICITY; SPLEEN; SWINE;

ANIMALIA; CANIS FAMILIARIS; MUS; RATTUS; SUIDAE; SUS;

EID: 75649105408     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498250903402266     Document Type: Article

References (30)

1. Balasubramanian AS, Bhanumathy CD. (1993). Noncholinergic functions of cholinesterases. FASEB J 7(14):1354-1358
2. Benvenuti S, Comoglio PM. (2007). The MET receptor tyrosine kinase in invasion and metastasis. J Cell Physiol 213(2):316-325
3. Camenisch G, Alsenz J, van de Waterbeemd H, Folkers G. (1998). Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs' lipophilicity and molecular weight. Eur J Pharm Sci 6(4):317-324
4. Clement B, Demesmaeker M, Linne S. (1996). Microsomal catalysed N-hydroxylation of guanabenz and reduction of the N-hydroxylated metabolite: characterization of the two reactions and genotoxic potential of guanoxabenz. Chem Res Toxicol 9(4):682-688
5. Edvinsson L. (2009). Migraine: telcagepant provides new hope for people with migraine. Nat Rev Neurol 5(5):240-242
6. Ekins S, Williams JA, Murray GI, Burke MD, Marchant NC, Engeset J, Hawksworth GM. (1996). Xenobiotic metabolism in rat, dog, and human precision-cut liver slices, freshly isolated hepatocytes, and vitrified precision-cut liver slices. Drug Metab Dispos 24(9):990-995
7. Elvin P, Garner AP. (2005). Tumour invasion and metastasis: challenges facing drug discovery. Curr Opin Pharmacol 5(4):374-381
8. Fang J, Gorrod JW. (1991). Dehydration is the first step in the bioactivation of haloperidol to its pyridinium metabolite. Toxicol Lett 59(1-3):117-123
9. Fingleton B. (2008). MMPs as therapeutic targets-still a viable option? Semin Cell Dev Biol 19(1):61-68
10. Förbs D, Thiel S, Stella MC, Stürzebecher A, Schweinitz A, Steinmetzer T, Stürzebecher J, Uhland K. (2005). In vitro inhibition of matriptase prevents invasive growth of cell lines of prostate and colon carcinoma. Int J Oncol 27(4):1061-1070
11. Guengerich FP. (1997). Comparisons of catalytic selectivity of cytochrome P450 subfamily enzymes from different species. Chem Biol Interact 106(3):161-182
12. Inoue M, Morikawa M, Tsuboi M, Sugiura M. (1979). Species difference and characterization of intestinal esterase on the hydrolizing activity of ester-type drugs. Jpn J Pharmacol 29(1):9-16.
13. Lee MS. (2006). Matrix-degrading type II transmembrane serine protease matriptase: its role in cancer development and malignancy. J Cancer Mol 2(5):183-190
14. Lee SL, Dickson RB, Lin CY. (2000). Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J Biol Chem 275(47):36720-36725
15. Levine WG. (1978). Biliary excretion of drugs and other xenobiotics. Annu Rev Pharmacol Toxicol 18:81-96.
16. Lewis DF, Jacobs MN, Dickins M. (2004). Compound lipophilicity for substrate binding to human P450s in drug metabolism. Drug Discov Today 9(12):530-537
17. Masson P, Froment MT, Darvesh S, Schopfer LM, Lockridge O. (2007). Aryl acylamidase activity of human serum albumin with o-nitrotrifluoroacetanilide as the substrate. J Enzyme Inhib Med Chem 22(4):463-469 (Pubitemid 47225710)
18. Minagawa T, Kohno Y, Suwa T, Tsuji A. (1995). Species differences in hydrolysis of isocarbacyclin methyl ester (TEI-9090) by blood esterases. Biochem Pharmacol 49(10):1361-1365
19. Misra RN, Xiao HY, Kim KS, Lu S, Han WC, Barbosa SA, Hunt JT, Rawlins DB, Shan W, Ahmed SZ, Qian L, Chen BC, Zhao R, Bednarz MS, Kellar KA, Mulheron JG, Batorsky R, Roongta U, Kamath A, Marathe P, Ranadive SA, Sack JS, Tokarski JS, Pavletich NP, Lee FY, Webster KR, Kimball SD. (2004). N-(cycloalkylamino)acyl-2- aminothiazole inhibitors of cyclindependent kinase 2. N-[5-[[[5-(1,1- dimethylethyl)-2-oxazolyl] methyl]thio]-2-thiazolyl]-4-piperidinecarbox-amide (BMS-387032), a highly efficacious and selective antitumor agent. J Med Chem 47(7):1719-1728
20. Monshouwer M, van't Klooster G, Nijmeijer SM, Witkamp RF, van Miert A. (1998). Characterization of cytochrome P450 isoenzymes in primary cultures of pig hepatocytes. Toxicol In Vitro 12:712-723
21. Myers MJ, Farrell DE, Howard KD, Kawalek JC. (2001). Identification of multiple constitutive and inducible hepatic cytochrome P450 enzymes in market weight swine. Drug Metab Dispos 29(6):908-915
22. Olsen AK, Hansen KT, Friis C. (1997). Pig hepatocytes as an in vitro model to study the regulation of human CYP3A4: prediction of drug-drug interactions with 17 alpha-ethynylestradiol. Chem Biol Interact 107(1-2):93-108.
23. Skrzydlewska E, Sulkowska M, Koda M, Sulkowski S. (2005). Proteolytic-antiproteolytic balance and its regulation in carcinogenesis. World J Gastroenterol 11(9):1251-1266
24. Smith DA. (1991). Species differences in metabolism and pharmacokinetics: are we close to an understanding? Drug Metab Rev 23(3-4):355-373
25. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ, Klenk DC. (1985). Measurement of protein using bicinchoninic acid. Anal Biochem 150(1):76-85.
26. Steinmetzer T, Schweinitz A, Stürzebecher A, Dönnecke D, Uhland K, Schuster O, Steinmetzer P, Müller F, Friedrich R, Than ME, Bode W, Stürzebecher J. (2006). Secondary amides of sulfonylated 3-amidinophenylalanine. New potent and selective inhibitors of matriptase. J Med Chem 49(14):4116-4126
27. Testa B. (1994). The metabolism of drugs and other xenobiotics. Biochemistry of redox reactions. New York, NY: Academic Press. p. 122-163
28. Uhland K. (2006). Matriptase and its putative role in cancer. Cell Mol Life Sci 63(24):2968-2978
29. Zhang D, Wang L, Raghavan N, Zhang H, Li W, Cheng PT, Yao M, Zhang L, Zhu M, Bonacorsi S, Yeola S, Mitroka J, Hariharan N, Hosagrahara V, Chandrasena G, Shyu WC, Humphreys WG. (2007). Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. Drug Metab Dispos 35(1):150-167
30. Zuber R, Anzenbacherova E, Anzenbacher P. (2002). Cytochromes P450 and experimental models of drug metabolism. J Cell Mol Med 6(2):189-198